Child Health Foundation Panel Recommends Infant Formula Contain DHA and AA

Apr 25, 2001, 01:00 ET from Martek Biosciences Corporation

    COLUMBIA, Md., April 25 /PRNewswire/ -- Martek Biosciences Corporation
 (Nasdaq:   MATK) announced today that an international panel of child and
 maternal health experts has recommended that infant formula be enriched with
 both docosahexaenoic acid (DHA) and arachidonic acid (AA).  A paper presenting
 this recommendation was published in the April 2001 issue of Acta Paediatrica
 and is the result of a scientific workshop organized and supported by the
 independent Child Health Foundation of Munich, Germany.  An abstract of this
 paper can be accessed through a link from Martek's website at:
 http://www.martekbio.com/financials.html .
     This recommendation, presented in the paper "Long Chain Polyunsaturated
 Fatty Acids (LC-PUFA) and Perinatal Development," represents a comprehensive
 summary of the current status of LC-PUFAs and their role in maternal and child
 health.  Two LC-PUFAs, DHA and AA, essential nutritional components of breast-
 milk, are believed by many researchers to enhance mental and visual
 development in infants and play a pivotal role in brain function throughout
 life.  For healthy infants, the panel recommended and strongly supported
 breast-feeding as the preferred feeding method.  For those infants that are
 formula fed, the panel recommended the use of infant formula that contains
 both DHA and AA.
     The panel also thought it prudent for pregnant and lactating women to
 obtain an adequate dietary supply of DHA, although they made no specific
 recommendation in this regard.  In addition, they stated that high intakes of
 eicosapentaenoic acid (EPA), an LC-PUFA found in fish oil-related products,
 are not desirable for infant feeding.
     "The DHA and AA recommendation of the Child Health Foundation's panel
 provides a real service to improving infant nutrition," stated Henry Linsert,
 Jr., Chairman and CEO of Martek.  "Martek's pure, vegetarian DHA and AA are
 the perfect source for these infant formula ingredients."
     Martek Biosciences Corporation develops, manufactures and sells products
 from microalgae.  The Company's products include: (1) specialty, nutritional
 oils for infant formula, nutritional supplements and food ingredients that may
 play a beneficial role in promoting mental and cardiovascular health, and in
 the development of the eyes and central nervous system in newborns; (2) high
 value reagents and technologies to visualize molecular interactions for drug
 discovery and development and; (3) new, powerful fluorescent markers for
 diagnostics, rapid miniaturized screening, and gene and protein detection.
     This press release contains forward-looking statements regarding potential
 benefits of Martek's oils.  Such statements involve risks and uncertainties
 that could cause future actual results to differ due to a variety of risk
 factors, including without limitations those factors set forth in Exhibit 99.1
 to the Company's Form 10-Q for the fiscal quarter ended January 31, 2001 and
 from time to time in the Company's filings with the Securities and Exchange
 Commission.
 
 

SOURCE Martek Biosciences Corporation
    COLUMBIA, Md., April 25 /PRNewswire/ -- Martek Biosciences Corporation
 (Nasdaq:   MATK) announced today that an international panel of child and
 maternal health experts has recommended that infant formula be enriched with
 both docosahexaenoic acid (DHA) and arachidonic acid (AA).  A paper presenting
 this recommendation was published in the April 2001 issue of Acta Paediatrica
 and is the result of a scientific workshop organized and supported by the
 independent Child Health Foundation of Munich, Germany.  An abstract of this
 paper can be accessed through a link from Martek's website at:
 http://www.martekbio.com/financials.html .
     This recommendation, presented in the paper "Long Chain Polyunsaturated
 Fatty Acids (LC-PUFA) and Perinatal Development," represents a comprehensive
 summary of the current status of LC-PUFAs and their role in maternal and child
 health.  Two LC-PUFAs, DHA and AA, essential nutritional components of breast-
 milk, are believed by many researchers to enhance mental and visual
 development in infants and play a pivotal role in brain function throughout
 life.  For healthy infants, the panel recommended and strongly supported
 breast-feeding as the preferred feeding method.  For those infants that are
 formula fed, the panel recommended the use of infant formula that contains
 both DHA and AA.
     The panel also thought it prudent for pregnant and lactating women to
 obtain an adequate dietary supply of DHA, although they made no specific
 recommendation in this regard.  In addition, they stated that high intakes of
 eicosapentaenoic acid (EPA), an LC-PUFA found in fish oil-related products,
 are not desirable for infant feeding.
     "The DHA and AA recommendation of the Child Health Foundation's panel
 provides a real service to improving infant nutrition," stated Henry Linsert,
 Jr., Chairman and CEO of Martek.  "Martek's pure, vegetarian DHA and AA are
 the perfect source for these infant formula ingredients."
     Martek Biosciences Corporation develops, manufactures and sells products
 from microalgae.  The Company's products include: (1) specialty, nutritional
 oils for infant formula, nutritional supplements and food ingredients that may
 play a beneficial role in promoting mental and cardiovascular health, and in
 the development of the eyes and central nervous system in newborns; (2) high
 value reagents and technologies to visualize molecular interactions for drug
 discovery and development and; (3) new, powerful fluorescent markers for
 diagnostics, rapid miniaturized screening, and gene and protein detection.
     This press release contains forward-looking statements regarding potential
 benefits of Martek's oils.  Such statements involve risks and uncertainties
 that could cause future actual results to differ due to a variety of risk
 factors, including without limitations those factors set forth in Exhibit 99.1
 to the Company's Form 10-Q for the fiscal quarter ended January 31, 2001 and
 from time to time in the Company's filings with the Securities and Exchange
 Commission.
 
 SOURCE  Martek Biosciences Corporation